Transforming lives by accelerating innovation in cardiometabolic health

About

Obesity and its associated complications comprise some of the world’s most pressing health issues.

We created Verdiva Bio to accelerate the development of differentiated medicines that address the significant unmet medical needs in this space.

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.

The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options to transform the lives of millions.

Verdiva’s most advanced therapy in development is VRB-101, an oral GLP-1 peptide that has demonstrated compelling efficacy potential in a phase 1 study, which also confirmed the viability of once-weekly dosing.

The company’s portfolio includes multiple amylin molecules (oral and subcutaneous agonists) and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss.

Pipeline

Potential best-in-class therapies for cardiometabolic conditions

Program
MoA
Dosing
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
VRB-101
(Oral)
GLP-1
Once-weekly peptide
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Ph 2-ready

VRB-101 (Oral)

VRB-101 is an oral, once-weekly GLP-1 receptor agonist in clinical development for obesity

VRB-103
(Oral)
Amylin (DACRA)
Once-weekly peptide
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
IND-enabling

VRB-103 (Oral)

VRB-103 is an oral, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for use as monotherapy or in combination with oral GLP-1 therapy for obesity

VRB-103 + VRB-101
(Oral)
Amylin + GLP-1
Once-weekly or daily
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
IND-enabling

VRB-103 + VRB-101 (Oral)

Verdiva Bio is testing an oral daily or once-weekly combination therapy of VRB-103 and VRB-101 in obesity

VRB-102 + VRB-101
(Injectable)
Amylin* + GLP-1
Once-weekly peptide(s)
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
IND-enabling

VRB-102 + VRB-101 (injectable)

VRB-102 is an injectable, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for use as monotherapy or in combination with VRB-101 for obesity

*Dual amylin and calcitonin receptor against (DACRA) agent

Team

Leadership
Board

Leadership

Khurem Farooq

Chief Executive Officer

Jane Hughes

Chief Scientific Officer

Mohamed Eid, MD

Chief Medical Officer

Ashley Taylor

Chief Technology Officer

Tapan Maniar

Chief Business Officer

Andrew Prosser

SVP, Head of Finance

Elaine Johnston

General Counsel

Board

Mark Pruzanski, MD

Board Chair

Khurem Farooq

 Chief Executive Officer

Wouter Joustra

General Partner, Forbion

Brett Zbar, MD

Managing Director and Global Head of Life Sciences, General Atlantic

Laura Stoppel

Partner at RA Capital Management, L.P.

Carl Gordon

Managing Partner, OrbiMed

Graham Walmsley, MD

Co-Founder & Managing Partner at Logos Capital

Investors

Forbion.
GENERAL ATLANTIC
RACAPITAL
orbimed
LOGOS CAPITAL
Lilly Asia Ventures
LYFE CAPITAL

News

9 January 2025

Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies

Contact

Do you have questions or want to learn more about our transformative work?

Reach out to us using the form here. We value your input and are excited to engage with like-minded individuals, potential partners, and collaborators who share our passion for innovation in metabolic disease research.

Please enable JavaScript in your browser to complete this form.